These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Keene CD; Rodrigues CM; Eich T; Chhabra MS; Steer CJ; Low WC Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10671-6. PubMed ID: 12149470 [TBL] [Abstract][Full Text] [Related]
10. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160 [TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221 [TBL] [Abstract][Full Text] [Related]
12. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507 [TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. Ferrante RJ; Andreassen OA; Jenkins BG; Dedeoglu A; Kuemmerle S; Kubilus JK; Kaddurah-Daouk R; Hersch SM; Beal MF J Neurosci; 2000 Jun; 20(12):4389-97. PubMed ID: 10844007 [TBL] [Abstract][Full Text] [Related]
14. LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease. Chopra V; Quinti L; Khanna P; Paganetti P; Kuhn R; Young AB; Kazantsev AG; Hersch S J Huntingtons Dis; 2016 Dec; 5(4):347-355. PubMed ID: 27983565 [TBL] [Abstract][Full Text] [Related]
16. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease. Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809 [TBL] [Abstract][Full Text] [Related]
17. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. Simmons DA; Belichenko NP; Yang T; Condon C; Monbureau M; Shamloo M; Jing D; Massa SM; Longo FM J Neurosci; 2013 Nov; 33(48):18712-27. PubMed ID: 24285878 [TBL] [Abstract][Full Text] [Related]
18. Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice. Wang H; Del Mar N; Deng Y; Reiner A Neurosci Lett; 2021 Oct; 763():136180. PubMed ID: 34416343 [TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of levothyroxine on cognition deficits and memory in an experimental model of Huntington's disease in rats: An electrophysiological study. Badini F; Mirshekar MA; Shahraki S; Fanaei H; Bayrami A Naunyn Schmiedebergs Arch Pharmacol; 2024 Aug; 397(8):5939-5951. PubMed ID: 38372755 [TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington's disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway. Saroj P; Bansal Y; Singh R; Akhtar A; Sodhi RK; Bishnoi M; Sah SP; Kuhad A Inflammopharmacology; 2021 Apr; 29(2):499-511. PubMed ID: 33517508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]